GSK discontinues genital herpes vaccine after Phase III failure
This article was originally published in Scrip
The most advanced vaccine in development to protect against genital herpes disease in woman, GlaxoSmithKline's Simplirix, has unexpectedly failed in a large Phase III trial, leading the company to discontinue its development.
You may also be interested in...
Company will focus on getting oral anti-fungal candidate VL-2397 over the finish line, after another pipeline blow-up.
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.